Introduction Sometimes, inventors need to publicly disclose their invention publicly before filing a patent application—whether to present at conferences, seek funding, test the market, or demonstrate innovations to collaborators. Normally, such public disclosure destroys novelty and makes the invention unpatentable. However, the Indian Patents Act, 1970 recognizes that early disclosure may be unavoidable. To address […]
Introduction In a recent development for biologics patents in India, the Delhi High Court has granted interim relief to E.R. Squibb in their infringement suit1 against Zydus Lifesciences. The suit concerns IN 340060, which claims the monoclonal antibody Nivolumab—commercially known as Opdivo®—used in immunotherapy for various cancers. On July 18, 2025, the Court restrained Zydus […]
Kan and Krishme successfully represents patentee in landmark post-grant opposition against Indian pharmaceutical companies: Introduction The Indian Patent Office (IPO) has upheld Indian Patent No. 315447 in favor of Celator Pharmaceuticals Inc., dismissing post-grant oppositions filed by Cipla Ltd. and Mylan Laboratories Ltd. This landmark ruling affirms the strength of Celator’s patent covering its novel […]